Gestational diabetes incidence: molecular mechanisms & dependencies

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

Human evidence only

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

The 2013 trial reported gestational diabetes in 6% of the myo-inositol-plus-folic-acid group versus 15.3% with folic acid alone.
Myo-inositol → Gestational diabetes incidence source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/inositol-research/23340885.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "384eb5d40ed312af297e2ecdd98b1c3f804fda5555db8984de47dc08c3cdf336", "start_char": 0, "end_char": 1685, "text_sha256": "384eb5d40ed312af297e2ecdd98b1c3f804fda5555db8984de47dc08c3cdf336"}
experimental_model
Prospective randomized open-label pregnancy trial
exposure
Myo-inositol plus folic acid versus folic acid alone
limitations
Open-label design and selected risk group; this is neither an inositol-versus-folate comparison nor proof of a nutrient interaction.
nutrient_topic
Inositol research collection; topical membership is not evidence of a direct dietary effect. · Inositol (stereoisomer family)
organism
Homo sapiens
plain_language
An early trial suggested benefit in one risk group, with folic acid present in both groups.
primary_references
[ino-p23340885] myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. (2013). https://pubmed.ncbi.nlm.nih.gov/23340885/ DOI: 10.2337/dc12-1371
tissue_or_cell_type
Pregnant women with a family history of type 2 diabetes
Inositol: synthesis, signaling, mineral interactions and conditional deficiency (2026-09-17) · lines 1328–1339
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Prospective randomized open-label pregnancy trial · source_derived_draft · unverified_draft
### ino-gdm-2013 The 2013 trial reported gestational diabetes in 6% of the myo-inositol-plus-folic-acid group versus 15.3% with folic acid alone. Condition category: normal nutrient_topic: Inositol research collection; topical membership is not evidence of a direct dietary effect. plain_language: An early trial suggested benefit in one risk group, with folic acid present in both groups. organism: Homo sapiens tissue_or_cell_type: Pregnant women with a family history of type 2 diabetes experimental_model: Prospective randomized open-label pregnancy trial limitations: Open-label design and selected risk group; this is neither an inositol-versus-folate comparison nor proof of a nutrient interaction. exposure: Myo-inositol plus folic acid versus folic acid alone evidence_span: {"source_cache": "artifacts/inositol-research/23340885.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "384eb5d40ed312af297e2ecdd98b1c3f804fda5555db8984de47dc08c3cdf336", "start_char": 0, "end_char": 1685, "text_sha256": "384eb5d40ed312af297e2ecdd98b1c3f804fda5555db8984de47dc08c3cdf336"} [ino-p23340885] myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. (2013). https://pubmed.ncbi.nlm.nih.gov/23340885/ DOI: 10.2337/dc12-1371
Complete structured claim and evidence
MiGDM found no significant GDM difference among 43 completers, but early funding-related termination prevented a definitive efficacy test.
Myo-inositol → Gestational diabetes incidence source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/inositol-research/41742988.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "3b78fed7bce4eedabdbeae7d6e7e562bee8153fa1d0d805b5e96a52004344b29", "start_char": 0, "end_char": 3433, "text_sha256": "3b78fed7bce4eedabdbeae7d6e7e562bee8153fa1d0d805b5e96a52004344b29"}
experimental_model
MiGDM double-blind randomized pilot
exposure
Myo-inositol 2 g twice daily versus placebo; stopped early for funding
limitations
Only 67 enrolled and 43 completed versus 640 planned. Severe underpowering makes the result inconclusive, not proof of equivalence.
nutrient_topic
Inositol research collection; topical membership is not evidence of a direct dietary effect. · Inositol (stereoisomer family)
organism
Homo sapiens
plain_language
This small unfinished trial cannot settle whether the supplement works.
primary_references
[ino-p41742988] The Effect of Myo-Inositol Supplementation During Pregnancy on Fetal and Maternal Outcomes: Results of the Myo-Inositol for the Prevention of Gestational Diabetes Mellitus (MiGDM) Randomized Double-Blind, Placebo-Controlled Pilot Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41742988/ DOI: 10.7759/cureus.102259
tissue_or_cell_type
Pregnant women in Qatar
Inositol: synthesis, signaling, mineral interactions and conditional deficiency (2026-09-17) · lines 1354–1365
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · MiGDM double-blind randomized pilot · source_derived_draft · unverified_draft
### ino-gdm-2026 MiGDM found no significant GDM difference among 43 completers, but early funding-related termination prevented a definitive efficacy test. Condition category: normal nutrient_topic: Inositol research collection; topical membership is not evidence of a direct dietary effect. plain_language: This small unfinished trial cannot settle whether the supplement works. organism: Homo sapiens tissue_or_cell_type: Pregnant women in Qatar experimental_model: MiGDM double-blind randomized pilot limitations: Only 67 enrolled and 43 completed versus 640 planned. Severe underpowering makes the result inconclusive, not proof of equivalence. exposure: Myo-inositol 2 g twice daily versus placebo; stopped early for funding evidence_span: {"source_cache": "artifacts/inositol-research/41742988.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "3b78fed7bce4eedabdbeae7d6e7e562bee8153fa1d0d805b5e96a52004344b29", "start_char": 0, "end_char": 3433, "text_sha256": "3b78fed7bce4eedabdbeae7d6e7e562bee8153fa1d0d805b5e96a52004344b29"} [ino-p41742988] The Effect of Myo-Inositol Supplementation During Pregnancy on Fetal and Maternal Outcomes: Results of the Myo-Inositol for the Prevention of Gestational Diabetes Mellitus (MiGDM) Randomized Double-Blind, Placebo-Controlled Pilot Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/41742988/ DOI: 10.7759/cureus.102259
Complete structured claim and evidence

The events it takes part in

A mechanism often involves more than two components. These are the full events, with every participant and its role.

Situations it appears in

Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

Open hypotheses

Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.

This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

Gestational diabetes incidence